Literature DB >> 12632024

Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy.

Frank Kuepper1, George Dangas, Ansgar Mueller-Chorus, Peter M Kulka, Michael Zenz, Albrecht Wiebalck.   

Abstract

Low-dose aprotinin inhibits hyperfibrinolysis in cardiac surgery. However, excessive postoperative bleeding and increased fibrinolysis may occur despite low dose-aprotinin administration. We investigated (i) whether fibrinolytic activity significantly rises under low-dose aprotinin administration, and (ii) whether this is associated with excessive postoperative bleeding (> or = 1000 ml/24 h). In a prospective single-blind trial, 120 consecutive patients were randomized to receive 280 mg aprotinin or no aprotinin before skin incision. D-dimer levels increased significantly to the end of surgery, reaching higher levels in the control group. The risk for excessive bleeding was lower in the aprotinin group (12 versus 37%, = 0.001). Fifteen minutes after heparin reversal, patients were at risk for excessive bleeding, when enhanced fibrinolysis was documented (aprotinin group, D-dimer > or = 1.0 micro g/ml, odds ratio = 9.1, = 0.047; control group, D-dimer > or = 3.0 micro g/ml, odds ratio = 4.6, = 0.014). Ninety-seven per cent of the aprotinin group and 81% of control group patients had no excessive bleeding when the D-dimer plasma level was below these values. We conclude that (i) fibrinolytic activity significantly rises under low-dose aprotinin administration, and (ii) plasma D-dimer levels at end of surgery may help to identify patients who are unlikely to develop excessive postoperative bleeding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632024     DOI: 10.1097/00001721-200302000-00005

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

Review 1.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 2.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

3.  Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial.

Authors:  Juan J Jiménez; José L Iribarren; Maitane Brouard; Domingo Hernández; Salomé Palmero; Alejandro Jiménez; Leonardo Lorente; Patricia Machado; Juan M Borreguero; José M Raya; Beatriz Martín; Rosalía Pérez; Rafael Martínez; María L Mora
Journal:  J Cardiothorac Surg       Date:  2011-10-14       Impact factor: 1.637

4.  PAI-1 and t-PA/PAI-1 complex potential markers of fibrinolytic bleeding after cardiac surgery employing cardiopulmonary bypass.

Authors:  Agnese Ozolina; Eva Strike; Inta Jaunalksne; Angelika Krumina; Lars J Bjertnaes; Indulis Vanags
Journal:  BMC Anesthesiol       Date:  2012-10-30       Impact factor: 2.217

5.  Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study.

Authors:  Juan J Jimenez Rivera; Jose L Iribarren; Jose M Raya; Ibrahim Nassar; Leonardo Lorente; Rosalia Perez; Maitane Brouard; Jose M Lorenzo; Pilar Garrido; Ysamar Barrios; Maribel Diaz; Blas Alarco; Rafael Martinez; Maria L Mora
Journal:  J Cardiothorac Surg       Date:  2007-04-10       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.